Search

Researchers from Anhui Medical University in China have developed a novel radiotracer called Ga-68-DOTA-icatibant for imaging and therapy of liver cancer. The radiotracer targets the bradykinin B2 receptor (B2R), which is overexpressed in various tumors. The researchers found that Ga-68-DOTA-icatibant showed high stability, fast clearance, and specific binding to B2R. PET/MR imaging using the radiotracer accurately monitored the efficacy of anti-B2R therapy in inhibiting tumor growth. This research provides a noninvasive method for quantifying B2R expression and monitoring the effectiveness of anti-B2R therapy in liver cancer. [Extracted from the article]

A patent application titled "Prolyl Hydroxylase Domain Inhibitor Treatment To Improve Survivability Of Hemorrhagic Shock" proposes a combination of drugs to improve the survivability of combat casualties with potentially survivable injuries, specifically those associated with hemorrhage. The method involves controlling hemorrhage, administering resuscitation fluids, and using specific compositions of drugs such as prolyl hydroxylase domain inhibitors, antifibrinolytic agents, bradykinin receptor antagonists, calcium supplements, and volume expanders/resuscitation fluids. The application also describes a kit for administering these compositions in pre-hospital settings and surgery rooms to reduce blood loss and promote recovery. This method aims to extend survival time and improve outcomes for individuals experiencing hemorrhagic shock. [Extracted from the article]

This document provides information about a non-interventional study on the treatment of Hereditary Angioedema (HAE) in Chinese individuals. The study will collect data from medical records of participants who have received lanadelumab or icatibant, two approved medications for HAE. The study aims to assess the effectiveness and safety of these medications in real-world clinical practice. The study is expected to be completed by August 2025 and data sharing will be available to qualified researchers. The responsible party for the study is Takeda, a pharmaceutical company. [Extracted from the article]

A recent study conducted at the Federal University of Sao Paulo has explored the effects of Bradykinin B2 receptor ablation from tyrosine hydroxylase cells on behavioral and motor aspects in male and female mice. The researchers found that the deletion of B2 receptors in these cells selectively influenced body weight and composition, but did not significantly impact behavioral or motor aspects. The study suggests that the kallikrein-kinin system, which regulates various biological processes, may interact with the dopaminergic pathway. However, further research is needed to fully understand the implications of this interaction. [Extracted from the article]

A patent has been issued for Bradykinin B2 receptor antagonists by Pharvaris Netherlands B.V. The invention aims to provide novel BK B2 receptor antagonists with improved properties for the treatment of conditions such as angioedema. The patent describes the background and need for these antagonists, as well as the compounds and pharmaceutical compositions involved. The invention offers potential therapeutic benefits for various pathological conditions, including asthma, allergic rhinitis, osteoarthritis, and Alzheimer's disease. [Extracted from the article]

Researchers from Fayoum University have published a study on lung injury caused by bisphenol A (BPA), a chemical compound commonly found in plastics and epoxy resins. The study aimed to investigate the role of the renin-angiotensin system (RAS) in BPA-induced lung damage and inflammation. The researchers conducted an eight-week study on Wistar rats and found that BPA impaired lung structure, increased the expression of ACE, ACE2, and caspase-3 genes, and elevated inflammatory cytokines and oxidative markers. Treatment with the ACE inhibitor captopril and the angiotensin receptor blocker losartan showed promising results in mitigating lung injury. The study suggests that the RAS, specifically the ACE2/ACE imbalance, contributes to BPA-induced lung damage. [Extracted from the article]

Osaka, Japan, Asia, Angioedema, Angioneurotic Edema, Antiasthmatic Agents, Bradykinin B2 Receptor, Business, Cardiovascular Diseases and Conditions, Clinical Research, Clinical Trials and Studies, Drugs and Therapies, Genetic Diseases and Conditions, Health and Medicine, Hereditary Angioedema, Hereditary Angioedemas, Hypersensitivity, Immune System Diseases and Conditions, Pediatrics, Pharmaceutical Companies, Pharmacokinetics, Pharmacology, Skin Diseases and Conditions, Skin and Connective Tissue Diseases and Conditions, Urticaria, Vascular Skin Diseases and Conditions Keywords: Osaka; Japan; Asia; Angioedema; Angioneurotic Edema; Antiasthmatic Agents; Bradykinin B2 Receptor; Business; Cardiovascular Diseases and Conditions; Clinical Research; Clinical Trials and Studies; Drugs and Therapies; Genetic Diseases and Conditions; Health and Medicine; Hereditary Angioedema; Hereditary Angioedemas; Hypersensitivity; Immune System Diseases and Conditions; Pediatrics; Pharmaceutical Companies; Pharmacokinetics; Pharmacology; Skin Diseases and Conditions; Skin and Connective Tissue Diseases and Conditions; Urticaria; Vascular Skin Diseases and Conditions EN Osaka Japan Asia Angioedema Angioneurotic Edema Antiasthmatic Agents Bradykinin B2 Receptor Business Cardiovascular Diseases and Conditions Clinical Research Clinical Trials and Studies Drugs and Therapies Genetic Diseases and Conditions Health and Medicine Hereditary Angioedema Hereditary Angioedemas Hypersensitivity Immune System Diseases and Conditions Pediatrics Pharmaceutical Companies Pharmacokinetics Pharmacology Skin Diseases and Conditions Skin and Connective Tissue Diseases and Conditions Urticaria Vascular Skin Diseases and Conditions 463 463 1 07/31/23 20230731 NES 230731 2023 JUL 31 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Trials Week -- New research on Genetic Diseases and Conditions - Hereditary Angioedemas is the subject of a report. [Extracted from the article]

Christchurch, New Zealand, Australia and New Zealand, Angioedema, Angioneurotic Edema, Christchurch, Antiasthmatic Agents, Cardiovascular Diseases and Conditions, Drugs and Therapies, Health and Medicine, Hypersensitivity, Bradykinin B2 Receptor, Immune System Diseases and Conditions, Pediatrics, Skin Diseases and Conditions, Skin and Connective Tissue Diseases and Conditions, Urticaria, Vascular Skin Diseases and Conditions Keywords: Christchurch; New Zealand; Australia and New Zealand; Angioedema; Angioneurotic Edema; Antiasthmatic Agents; Bradykinin B2 Receptor; Cardiovascular Diseases and Conditions; Drugs and Therapies; Health and Medicine; Hypersensitivity; Immune System Diseases and Conditions; Pediatrics; Skin Diseases and Conditions; Skin and Connective Tissue Diseases and Conditions; Urticaria; Vascular Skin Diseases and Conditions EN Christchurch New Zealand Australia and New Zealand Angioedema Angioneurotic Edema Antiasthmatic Agents Bradykinin B2 Receptor Cardiovascular Diseases and Conditions Drugs and Therapies Health and Medicine Hypersensitivity Immune System Diseases and Conditions Pediatrics Skin Diseases and Conditions Skin and Connective Tissue Diseases and Conditions Urticaria Vascular Skin Diseases and Conditions 74 74 1 05/15/23 20230519 NES 230519 2023 MAY 20 (NewsRx) -- By a News Reporter-Staff News Editor at Pediatrics Week -- New research on Vascular Skin Diseases and Conditions - Angioedema is the subject of a report. [Extracted from the article]

Keywords: Barcelona; Spain; Europe; Antiasthmatic Agents; Bradykinin B2 Receptor; COVID-19; Clinical Research; Clinical Trials and Studies; Coronaviridae; Coronavirus; Drugs and Therapies; Health and Medicine; Infectious Disease; Lung Diseases and Conditions; Mortality; Nidovirales; Pneumonia; Pulmonology; RNA Viruses; Respiratory Tract Diseases and Conditions; Respiratory Tract Infections; Risk and Prevention; SARS-CoV-2; Severe Acute Respiratory Syndrome Coronavirus 2; Viral; Virology EN Barcelona Spain Europe Antiasthmatic Agents Bradykinin B2 Receptor COVID-19 Clinical Research Clinical Trials and Studies Coronaviridae Coronavirus Drugs and Therapies Health and Medicine Infectious Disease Lung Diseases and Conditions Mortality Nidovirales Pneumonia Pulmonology RNA Viruses Respiratory Tract Diseases and Conditions Respiratory Tract Infections Risk and Prevention SARS-CoV-2 Severe Acute Respiratory Syndrome Coronavirus 2 Viral Virology 29 29 1 03/23/23 20230320 NES 230320 2023 MAR 20 (NewsRx) -- By a News Reporter-Staff News Editor at NewsRx COVID-19 Weekly -- Current study results on Coronavirus - COVID-19 have been published. Barcelona, Spain, Europe, Antiasthmatic Agents, COVID-19, Clinical Research, Clinical Trials and Studies, Coronaviridae, Coronavirus, Drugs and Therapies, Health and Medicine, Infectious Disease, Lung Diseases and Conditions, Mortality, Nidovirales, Pneumonia, Pulmonology, RNA Viruses, Respiratory Tract Diseases and Conditions, Respiratory Tract Infections, Risk and Prevention, SARS-CoV-2, Severe Acute Respiratory Syndrome Coronavirus 2, Viral, Virology, Bradykinin B2 Receptor The randomized, open-label clinical trial of icatibant for COVID-19 pneumonia (ICAT center dot COVID, registered as NCT04978051 at ClinicalTrials.gov) was conducted in Barcelona.". [Extracted from the article]